JelikaLite was awarded the National Science Foundation SBIR Phase II grant
JelikaLite was awarded the National Science Foundation SBIR Phase II grant
Sign up for Early Access
banner banner

Get your free documentation on Cognilum®

JelikaLite it developing a photobiomodulation device for the increased well-being of children living with the developmental delays

Individuals
In this free documentation only intended for professionals, you will discover:
  • The Photobiomodulation therapy explained in details and its application to neurological disorders;
  • Results of past clinical trials;
  • Why FDA awarded Cognilum both Breakthrough Device Designation and Non-Significant Risk Device;
  • Its unique and novel technology at your service;
  • The areas of application for which Cognilum gets results;
Get your free documentation

Only intended for professionals

    In this free documentation only intended for individuals, you will:
    • Learn about Photobiomodulation therapy and its impact on social anxiety, instruction following, learning ability, verbal ability;
    • See testimonials from other parents;
    • Find a participating Professional in your geographical area.
    Get your free documentation

    Only intended for individuals

      info

      This statement has not been evaluated by the Food and Drug Administration.
      This product is not intended to diagnose, treat, cure, or prevent any disease.